共 50 条
- [1] X-PECT STUDY RESULTS: A PHASE III RANDOMIZED STUDY OF PERIFOSINE PLUS CAPECITABINE VS. PLACEBO PLUS CAPECITABINE IN REFRACTORY MCRC PATIENTSANNALS OF ONCOLOGY, 2012, 23 : 15 - 15Bendell, JohannaErvin, ThomasSenzer, NeilRichards, DonaldFirdaus, IrfanLockhart, A. CraigCohn, AllenSaleh, MansoorSportelli, PeterGardner, LesaEng, Cathy
- [2] Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC).JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Richards, D. A.Nemunaitis, J. J.Vukelja, S. J.Hagenstad, C. T.Campos, L. T.Letzer, J. P.Hermann, R. C.Sportelli, P.Gardner, L. R.Bendell, J. C.
- [3] Safety and pharmacokinetic (PK) study of perifosine plus capecitabine (P-CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC)JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Greco, F. A.Infante, J. R.Burris, H. A.Jones, S. F.Kolesar, J.Gardner, L. R.Sportelli, P.Bendell, J. C.
- [4] Impact of PI3K aberrations on efficacy of perifosine (P), x-PECT: A phase III randomized study of P plus capecitabine (PC) versus placebo plus capecitabine (C) in refractory metastatic colorectal cancer (mCRC) patients.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Eng, CathyBendell, Johanna C.Kopetz, ScottTarco, EmilyXiao, LianchunYing, JunWang, XuemeiPhillips, JonathanSportelli, PeterMeric-Bernstam, Funda
- [5] BACCI: A phase II randomized, double-blind, placebo-controlled study of capecitabine bevacizumab plus atezolizumab versus capecitabine bevacizumab plus placebo in patients with refractory metastatic colorectal cancer.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)Mettu, Niharika B.Niedzwiecki, DonnaBoland, Patrick MckayFakih, MarwanArrowood, ChristyBolch, EmilyHurwitz, HerbertGrothey, Axel
- [6] BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network studyANNALS OF ONCOLOGY, 2019, 30Mettu, N. B.Twohy, E.Ou, F-S.Halfdanarson, T. R.Lenz, H. J.Breakstone, R.Boland, P. M.Crysler, O.Wu, C.Grothey, A.Nixon, A. B.Bolch, E.Niedzwiecki, D.Fruth, B.Schweitzer, B.Elsing, A.Hurwitz, H.Fakih, M. G.Bekaii-Saab, T.
- [7] SUBSET ANALYSIS OF 5-FU REFRACTORY PATIENTS FROM A RANDOMIZED PH II STUDY OF PERIFOSINE plus CAPECITABINE (P-CAP) VS. PLACEBO plus CAPECITABINE (CAP) IN PATIENTS WITH 2ND OR 3RD LINE METASTATIC CRCANNALS OF ONCOLOGY, 2010, 21 : 16 - 16Hoff, P.Richards, D.Nemunaitis, J.Vukelja, S.Hagenstad, C.Campos, L.Letzer, J.Sportelli, P.Gardner, L.Bendell, J.
- [8] Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast CancerJOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) : 2459 - 2465Rugo, Hope S.Stopeck, Alison T.Joy, Anil A.Chan, StephenVerma, ShailendraLluch, AnnaLiau, Katherine F.Kim, SinilBycott, PaulRosbrook, BradBair, Angel H.Soulieres, Denis
- [9] A double-blind, randomized, prospective, phase II trail of capecitabine (Cap) plus enzastaurin (Enz) versus cap placebo in patients (pts) with advanced breast cancer (BrCa) and prior anthracycline and taxane treatmentJOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Clemons, M.Gelmon, K. A.Lynch, J.Kotliar, M. L.Joy, A.Jordaan, J. P.Han, L. L.Blair, J. M.Iscoe, N. A.
- [10] AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC)JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)Kang, Y.Ohtsu, A.Van Cutsem, E.Rha, S. Y.Sawaki, A.Park, S.Lim, H.Wu, J.Langer, B.Shah, M. A.